Clinical Trial

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has…

1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had…

1 year ago

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

Dr. Arshad Khanani to chair the newly formed Medical Advisory BoardMELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE)…

1 year ago

Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),…

1 year ago

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells…

1 year ago

Ancilia Biosciences Announces Closing of $4.2 Million Financing

Supports Development of Ancilia’s Unique Platform that Harnesses CRISPR’s Natural Function to Increase the Utility of Live Bacterial Products for Therapeutic…

1 year ago

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8

RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing…

1 year ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide…

1 year ago

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10…

1 year ago

Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development

BASEL, Switzerland – 17th July 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer…

1 year ago